ADAP
Price
$0.25
Change
-$0.01 (-3.85%)
Updated
Apr 7, 04:59 PM (EDT)
Capitalization
66.4M
38 days until earnings call
AKBA
Price
$1.78
Change
+$0.01 (+0.56%)
Updated
Apr 7, 04:59 PM (EDT)
Capitalization
462.38M
35 days until earnings call
Ad is loading...

ADAP vs AKBA

Header iconADAP vs AKBA Comparison
Open Charts ADAP vs AKBABanner chart's image
Adaptimmune Therapeutics
Price$0.25
Change-$0.01 (-3.85%)
Volume$12.18K
Capitalization66.4M
Akebia Therapeutics
Price$1.78
Change+$0.01 (+0.56%)
Volume$44.52K
Capitalization462.38M
ADAP vs AKBA Comparison Chart
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. AKBA commentary
Apr 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and AKBA is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 08, 2025
Stock price -- (ADAP: $0.26 vs. AKBA: $1.77)
Brand notoriety: ADAP and AKBA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 107% vs. AKBA: 167%
Market capitalization -- ADAP: $66.4M vs. AKBA: $462.38M
ADAP [@Biotechnology] is valued at $66.4M. AKBA’s [@Biotechnology] market capitalization is $462.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $283.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileAKBA’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • AKBA’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 5 TA indicator(s) are bullish while AKBA’s TA Score has 2 bullish TA indicator(s).

  • ADAP’s TA Score: 5 bullish, 3 bearish.
  • AKBA’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than AKBA.

Price Growth

ADAP (@Biotechnology) experienced а +25.29% price change this week, while AKBA (@Biotechnology) price change was -7.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.36%. For the same industry, the average monthly price growth was -17.88%, and the average quarterly price growth was -17.48%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 06, 2025.

AKBA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-9.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($462M) has a higher market cap than ADAP($66.4M). AKBA YTD gains are higher at: -6.842 vs. ADAP (-52.088). AKBA has higher annual earnings (EBITDA): -13.72M vs. ADAP (-55.9M). ADAP has more cash in the bank: 186M vs. AKBA (51.9M). AKBA has less debt than ADAP: AKBA (47.6M) vs ADAP (74.5M). ADAP has higher revenues than AKBA: ADAP (175M) vs AKBA (160M).
ADAPAKBAADAP / AKBA
Capitalization66.4M462M14%
EBITDA-55.9M-13.72M407%
Gain YTD-52.088-6.842761%
P/E RatioN/AN/A-
Revenue175M160M109%
Total Cash186M51.9M358%
Total Debt74.5M47.6M157%
FUNDAMENTALS RATINGS
ADAP vs AKBA: Fundamental Ratings
ADAP
AKBA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
9746
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (58) in the Biotechnology industry is in the same range as AKBA (70). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AKBA (100). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

ADAP's SMR Rating (94) in the Biotechnology industry is in the same range as AKBA (99). This means that ADAP’s stock grew similarly to AKBA’s over the last 12 months.

AKBA's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for ADAP (97). This means that AKBA’s stock grew somewhat faster than ADAP’s over the last 12 months.

AKBA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ADAP (100). This means that AKBA’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPAKBA
RSI
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
76%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
82%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 20 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
82%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
84%
View a ticker or compare two or three
Ad is loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AFVLX19.12-1.10
-5.44%
Applied Finance Select Investor
SWMCX58.06-3.60
-5.84%
Schwab ® US Mid-Cap Index
DRGVX40.91-2.76
-6.32%
BNY Mellon Dynamic Value Fund I
HLFNX24.92-1.85
-6.91%
Hennessy Large Cap Financial Investor
SOAEX10.69-1.02
-8.71%
Spirit of America Energy A

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-20.31%
AKBA - ADAP
38%
Loosely correlated
-5.85%
ORMP - ADAP
36%
Loosely correlated
-2.78%
ELEV - ADAP
34%
Loosely correlated
-3.29%
CSLLY - ADAP
32%
Poorly correlated
-7.01%
ERAS - ADAP
32%
Poorly correlated
-4.13%
More

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-5.85%
ABOS - AKBA
43%
Loosely correlated
-1.02%
ATOS - AKBA
40%
Loosely correlated
-6.44%
ADAP - AKBA
38%
Loosely correlated
-20.31%
OCGN - AKBA
38%
Loosely correlated
+3.65%
KOD - AKBA
35%
Loosely correlated
-2.08%
More